Best ADC Platform Technology

Winner: LigaChem Biosciences ConjuAllTM
Runner Up: Catalent SMARTag
Shortlisted: Abzena – ThioBridge, Ajinomoto Biopharma Services – AJICAP, Daiichi Sankyo – DXd ADC Technology, Sichuan Kelun-Biotech – optiDC, WuXi XDC - WuXiDAR4 Platform

Most Promising Clinical Candidate

Co-Winners: Raludotatug Deruxtecan, Daiichi Sankyo and Ifinatamab Deruxtecan, Daiichi Sankyo
Shortlisted: BL-B01D1 – SystImmune, MBRC-101 - MBrace Therapeutics, OBI-992 - OBI Pharma, Sacituzumab Tirumotecan - Sichuan Kelun-Biotech/ MSD

Best New Drug Developer

 Winner: Duality Biologics
Runner Up: ProfoundBio (Genmab)
Shortlisted: Exelixis, LigaChem Biosciences, MBrace Therapeutics, Sichuan Kelun-Biotech

Best Contract Research Organization

Co-Winners: NJ Bio Inc. and PPD
Shortlisted: Abzena, ChemExpress, Crown Bioscience, WuXi XDC

Best Contract Manufacturing Development Organization

Co-Winners: Lonza and WuXi XDC
Shortlisted: Abzena, AsymBio, Aton Biotech, BSP Pharmaceuticals, Cerbios AG, MilliporeSigma, Simtra BioPharma Solutions

Best ADC Preclinical Publication 2023

Winner: AJICAP Second Generation:
Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production
Runner Up: Antibody-Drug Conjugate Sacituzumab Govitecan Drives Efficient Tissue Penetration and Rapid Intracellular Drug Release

Best ADC Clinical Publication 2023

Winner: Efficacy and Safety of Mirvetuximab Soravtansine in Patients With Platinum-Resistant Ovarian Cancer With High Folate Receptor Alpha Expression: Results From the SORAYA Study
Runner Up: Trastuzumab Deruxtecan Versus Treatment of Physician's Choice in Patients with HER2-Positive Metastatic Breast Cancer (DESTINY-Breast02): a Randomised, Open-Label, Multicentre, Phase 3 Trial

Outstanding Academic Investigator Award

Winner: Joseph Balthasar, University at Buffalo

Best Poster 2024

Winner: Tub-040, a Novel napi2B-Targeting ADC Built With Ethynylphosphonamidate Conjugation Chemistry, Demonstrates High and Long-Lasting Anti-tumor Efficacy via Topoisomerase I Inhibition and Excellent Tolerability Predictive of a Wide Therapeutic Window in Humans

The George R Pettit Individual Input to the Field Award

Co-Winners: Andrew Polson, Genentech and Brian Mendelsohn, Exelixis

Long Standing Contribution to the Field Award

Winner: Morris Rosenberg